Have patients born before 1991?

Identifying patients just got easier.
The CDC now recommends UNIVERSAL adult hepatitis B vaccination1-3,*

Protecting your adult patients can be as

Protecting your adult patients can be as easy as 1, 2 Protecting your adult patients can be as easy as 1, 2

Patients born before 1991?
Use 2 doses, 1 month, done.1,3,4

WHY DO YOU NEED TO UNIVERSALLY VACCINATE?

While the 1991 pediatric policy helped decrease rates of hepatitis B in children, adults are still vulnerable and cases are on the rise5,6

In 2019

In 2019, approximately 50% of new cases were among adults aged 30 to 49 years In 2019, approximately 50% of new cases were among adults aged 30 to 49 years

of new cases were among adults aged 30 to 49 years5

In many states, the rate of new hepatitis B cases in adults has increased In many states, the rate of new hepatitis B cases in adults has increased

In many states, the rate of new cases in adults has increased in the last decade5,7

To combat the growing number of hepatitis B cases, the CDC now recommends universal hepatitis B vaccination for all adults.3,5,*

YOUR ROLE IS CRITICAL FOR PROTECTING THE ADULTS YOU SEE EVERY DAY IN YOUR PHARMACY

Millions of adults still need hepatitis B vaccination5,8,†

4 out of 5 adults born before 1991 do not have vaccine-induced immunity 4 out of 5 adults born before 1991 do not have vaccine-induced immunity

born before 1991 do not have vaccine-induced immunity6

The hepatitis B vaccine could become the most widely used non-flu vaccine for adults in your pharmacy.8,†

HEPATITIS B IS NOW A YEAR-ROUND, ROUTINE VACCINATION FOR ADULTS—START PROTECTING YOUR PATIENTS TODAY3

The CDC recommends hepatitis B vaccination for all adults aged 19-59 and adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.3

Adults eligible for influenza vaccines calculated from population aged 18+ in 2022; adults eligible for shingles vaccines calculated using adults turning 50 years old in 2022, adults aged >50 who are unvaccinated based on CDC coverage rates, and immunocompromised adults aged 19-49; adults eligible for pneumonia vaccines included adults aged 65+ and at-risk adults aged 18-64 excluding smokers, patients with chronic heart disease, and patients who are immunocompromised; adults eligible for hepatitis B vaccination calculated using US census data published in 2018, CDC coverage data, and risk factor analyses. COVID vaccines were not part of this analysis.8

ROUTINE HEPATITIS B PROTECTION STARTS WITH YOU3

Follow these steps to get your patients protected:

IDENTIFY

all patients born before 19911,3

Identify all patients born before 1991 Identify all patients born before 1991

RECOMMEND

A strong recommendation helps protect more patients9

Your strong recommendation helps protect more patients Your strong recommendation helps protect more patients

PROTECT

with HEPLISAV-B: 2 doses, 1 month, done4

Protect with HEPLISAV-B: 2 doses, 1 month, done. Protect with HEPLISAV-B: 2 doses, 1 month, done.

How to get the conversation started with your patients:

How to get the conversation started with your patients:

Based on your date of birth, you likely did not receive the hepatitis B vaccination series as a child. The CDC now recommends that adults get caught up, and I recommend that you get started today with HEPLISAV-B. It’s just 2 doses in 1 month and you’re done.1,3,4,‡

Elevate the success of your pharmacy: identify more patients, recommend vaccination, and protect with HEPLISAV-B1,3,4,9

The CDC recommends hepatitis B vaccination for all adults aged 19-59 and adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.3

PATIENTS BORN BEFORE 1991? USE 2 DOSES, 1 MONTH, DONE.1,3,4

HEPLISAV-B is the first and only 2-dose adult hepatitis B vaccine that provides series completion in just 1 month3,4,10

HEPLISAV-B is a 2-dose, 1-month hepatitis B vaccine and Engerix-B is a 3-dose, 6-month hepatitis B vaccine[2,8] HEPLISAV-B is a 2-dose, 1-month hepatitis B vaccine and Engerix-B is a 3-dose, 6-month hepatitis B vaccine[2,8]

Clinical studies have shown faster protection with HEPLISAV‑B4,12

EXPLORE DATA

ACCESS TO HEPLISAV-B

HEPLISAV-B is covered by most insurance plans and may be billed as a medical or prescription benefit (NDC#: 43528-0003-05)

HEPLISAV-B PROVIDES FASTER PROTECTION WITH AN EFFICIENT 2‑DOSE SERIES4,11,12

PHARMACISTS ARE CRITICAL TO THE SUCCESS OF THE UNIVERSAL ADULT HEPATITIS B VACCINATION POLICY3,§

Take the lead: identify patients, recommend vaccination, and start protecting today with HEPLISAV-B1,3,4,9

HEPLISAV-B comes in a package of 5 single-dose prefilled syringes HEPLISAV-B comes in a package of 5 single-dose prefilled syringes

Patients born before 1991?

Use 2 doses, 1 month, done.1,3,4

HEPLISAV-B NDC#: 43528-0003-05

Looking for more information on HEPLISAV-B?

Get Resources

The CDC recommends hepatitis B vaccination for all adults aged 19-59 and adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.3

 

Important Safety Information

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

References: 1. Immunization Practices Advisory Committee. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1-19. 2. Freedman M, Kroger A, Hunter P, Ault KA. Recommended adult immunization schedule, United States, 2020. Ann Intern Med. 2020;172(5):337-347. doi:10.7326/M20-0046 3. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2023. Accessed April 4, 2023. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf 4. HEPLISAV-B. Package insert. Dynavax Technologies Corporation; 2020. 5. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483. doi:10.15585/mmwr.mm7113a1 6. He WQ, Guo GN, Li C. The impact of hepatitis B vaccination in the United States, 1999-2018. Hepatology. 2022;75(6):1566-1578. doi:10.1002/hep.32265 7. Hepatitis B Foundation. Hepatitis B facts and figures. Accessed March 8, 2022. https://www.hepb.org/what-is-hepatitis-b/what-is-hepb/facts-and-figures 8. Data on file. Dynavax Technologies Corporation; 2023. 9. Bjork A, Morelli V. Immunization strategies for healthcare practices and providers. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Public Health Foundation; 2021:29-42. 10. Haber P, Schillie S. Hepatitis B. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Public Health Foundation; 2021:143-164. 11. Engerix-B. Package insert. GlaxoSmithKline; 2020. 12. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD.

See the CDC recommendation

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.